Propyl-substituted pyrrolidinone (high-affinity SV2A ligand)

Plain-language summaryIntrigue 65 / 100

Brivaracetam, sold as Briviact, is a propyl-substituted analog of levetiracetam with higher SV2A affinity. It is FDA-approved for partial-onset seizures and offers improved tolerability over levetiracetam in some patients. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

51/100

Superior SV2A probe over levetiracetam, FDA-approved, but an incremental advance in well-trodden antiepileptic territory

Look, brivaracetam is a genuinely well-executed optimization of levetiracetam, but “well-executed optimization of a 25-year-old approved drug” is exactly what keeps it out of the 70s. UCB Pharma’s medicinal chemistry work here was solid: the propyl substitution at C4 increases SV2A affinity roughly 15-fold (Kd 0.06 microM versus around 1 microM for levetiracetam), and the selectivity profile is cleaner across potential off-targets. FDA approved it as Briviact in February 2016 for partial-onset seizures, and the phase 3 data are unambiguous. That’s a real accomplishment. The problem, from a research interest perspective, is that the SV2A story is now well-established ground.

SV2A is genuinely interesting biology. Its role in calcium-dependent vesicle priming and the modulation of neurotransmitter release is still being refined at the molecular level – we dont fully understand how SV2A binding translates into the anticonvulsant effect, and that gap is worth filling. Brivaracetam’s tighter, more selective binding makes it a better probe for this work than levetiracetam, which is where we see the real research argument. If your program involves dissecting SV2A function in synaptic terminals or screening SV2A-interacting partners, you want the highest-affinity selective tool available, and brivaracetam wins that contest over the parent compound.

What we like: the behavioral and psychiatric side effect profile is meaningfully improved versus levetiracetam, with lower rates of irritability and depression at equivalent doses. That tells us something real about what those levetiracetam side effects were attributable to, possibly off-target activity that got cleaned up by the analog work. The PK is also clean: oral bioavailability is essentially complete, half-life around 9 hours, hepatic metabolism straightforward via amide hydrolysis and CYP2C19. Good experimental drug properties in a tool compound.

What keeps the score where it is: theres no new indication horizon here. The antiepileptic space for SV2A ligands is as mapped as its going to get for a first-line use case, and brivaracetam entered a market where levetiracetam was already going generic, offering a tolerability advantage in a subset of patients who hit psychiatric side effects. The clinical trials confirmed efficacy nobody doubted. The mechanistic questions that remain around SV2A are addressable with brivaracetam as a pharmacological tool, but that’s a probe use case, not a frontier indication story. Schedule V status makes sourcing and handling about as uncomplicated as a controlled antiepileptic gets.

Honestly, if you’re running SV2A biology and want a pharmacological tool that out-performs levetiracetam on target engagement and selectivity, brivaracetam earns a place on the bench. But it’s not a compound that’s going to redefine what you think is possible in its space.

Novelty: 27
Mechanism promise: 42
In-category differentiation: 48
Evidence quality: 77
Translational signal: 73
Research bench value: 52

Rationale Strong evidence base from multiple phase 3 RCTs and FDA approval boosts evidence and translational scores, but brivaracetam is a 10-year-old analog of a 25-year-old drug operating on a mechanism the field has largely mapped; novelty and differentiation are low, and the primary research argument is probe utility for SV2A biology rather than any frontier indication.

Propyl-substituted pyrrolidinone (high-affinity SV2A ligand)

A propyl-substituted levetiracetam analog with 15-fold higher SV2A affinity, FDA-approved 2016 as Briviact for partial-onset seizures.

Abstract

Brivaracetam (Briviact; UCB-34714; (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide; CAS 357336-20-0; molecular formula C11H20N2O2; molecular weight 212.29) is a propyl-substituted levetiracetam analog developed at UCB Pharma and approved by the FDA in February 2016 as adjunctive therapy for partial-onset seizures. Brivaracetam binds SV2A with approximately 15-fold higher affinity than levetiracetam (Kd 0.06 microM versus 1 microM) and shows higher selectivity for SV2A over other potential targets. The clinical consequence is improved seizure protection at lower doses with a flatter pharmacokinetic-pharmacodynamic relationship. Compared with levetiracetam, brivaracetam shows lower rates of behavioral and psychiatric adverse effects (irritability, depression), which are dose-limiting for some levetiracetam patients. Pharmacokinetics: plasma half-life 9 hours; oral bioavailability essentially complete; metabolism is hepatic via amide hydrolysis and CYP2C19. Approved doses are 50 to 200 mg per day in two divided administrations. Schedule V in the United States.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-034Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Propyl-substituted pyrrolidinone (high-affinity SV2A ligand)

Brivaracetam

Abstract

Read the full monograph